NACL Industries 39th AGM on July 22, 2026; FY26 Marks Strong Turnaround
NACL Industries Limited has scheduled its 39th AGM on July 22, 2026 via video conferencing. FY 2025-26 marked a strong turnaround with consolidated revenue of ₹1,58,446 Lakhs, EBITDA margin of 6.7%, and net profit of ₹457 Lakhs, supported by Coromandel International's majority stake acquisition, a ₹249.29 Crore rights issue, and credit rating upgrades to CRISIL AA/Stable. Export revenues grew 14% to ₹35,355 Lakhs across 39 countries, and nine new formulations were commercialized during the year.
*this image is generated using AI for illustrative purposes only.
NACL Industries Limited has announced the convening of its 39th Annual General Meeting (AGM) on Wednesday, July 22, 2026, at 03:30 P.M. IST. The meeting will be held through Video Conferencing (VC) / Other Audio-Visual Means (OAVM), with the registered office of the Company deemed to be the venue. The Company, established in 1993, has evolved into a diversified agrochemical company with a strong presence across domestic retail, institutional, and export markets, offering a portfolio of over 66 branded products spanning insecticides, herbicides, fungicides, and plant growth regulators.
AGM Key Details
The following table summarises the key logistics and agenda items for the 39th AGM:
| Parameter: | Details |
|---|---|
| Day and Date: | Wednesday, July 22, 2026 |
| Time: | 03:30 P.M. IST |
| Mode: | Video Conferencing / OAVM |
| Dividend for FY 2025-26: | NIL |
| Remote E-Voting Opens: | Sunday, July 19, 2026 at 09:00 A.M. IST |
| Remote E-Voting Closes: | Tuesday, July 21, 2026 at 05:00 P.M. IST |
| Record Date (Cut-off): | Friday, July 17, 2026 |
AGM Agenda
The business to be transacted at the AGM includes both ordinary and special items:
Ordinary Business:
- Adoption of Audited Standalone Financial Statements for the financial year ended March 31, 2026, along with the Auditors' Report and Board of Directors' Report
- Adoption of Audited Consolidated Financial Statements for the financial year ended March 31, 2026, along with the Auditors' Report
- Re-appointment of Mr. Sankarasubramanian S (DIN: 01592772), Non-Executive Director, who retires by rotation
Special Business:
- Ratification of remuneration of ₹8,00,000/- (Rupees Eight Lakhs only) plus applicable taxes payable to M/s. K. Narasimha Murthy & Co., Cost Auditors, for the financial year ending March 31, 2027
- Approval by Special Resolution of the revision in remuneration payable to Dr. Raghuram Devarakonda (DIN: 09749805), Managing Director & Chief Executive Officer, with effect from April 01, 2026
MD & CEO Remuneration Revision
The Board, on the recommendation of the Nomination and Remuneration Committee, approved a revision in the remuneration of Dr. Raghuram Devarakonda with effect from April 01, 2026. The key components of the revised remuneration structure are as follows:
| Component: | Details |
|---|---|
| Basic Salary (Fixed Compensation): | ₹14,32,900/- per month, with increments as recommended by the NRC and approved by the Board |
| Annual Performance Pay: | As determined by the NRC and approved by the Board, not higher than 70% of annual basic pay |
| Allowances and Perquisites: | Allowances including HRA, LTA, Special Allowances and others, subject to a maximum of 100% of Basic Salary |
| Retirement Benefits: | Contribution to Provident Fund, Superannuation Fund, Gratuity, and leave encashment as per Company rules |
| Stock Options: | As per the Company's Employee Stock Options Scheme/Plan, as decided by the NRC and Board |
Dr. Devarakonda's remuneration drawn during FY 2025-26 was ₹2,19,00,000.
FY 2025-26 Financial Performance
FY 2025-26 marked a significant turnaround for the Company. The acquisition of a majority stake by Coromandel International Limited strengthened stakeholder confidence, supported by a rights issue and improved credit ratings. The following table presents the consolidated financial performance:
| Particulars: | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Revenue from Operations (₹ in Lakhs): | 1,58,446 | 1,23,452 | 1,77,873 |
| EBITDA Margin: | 6.7% | -4.4% | 1.4% |
| Return on Capital Employed: | 5.7% | -6.6% | 0% |
| Return on Net Worth: | 0.7% | -21.6% | -11.5% |
| Earnings per Share (FV ₹1 each): | 0.21 | -4.27 | 2.96 |
| Book Value per Share: | 29 | 21 | 26 |
The consolidated profit before exceptional items and taxes stood at ₹2,718 Lakhs, compared to a loss of ₹14,883 Lakhs in the previous year. Net profit after tax was ₹457 Lakhs against a loss after tax of ₹9,213 Lakhs in FY 2024-25.
Operating Results Summary
The Board's Report presented the following consolidated and standalone operating results for FY 2025-26 (₹ in Lakhs):
| Particulars: | Consolidated FY26 | Consolidated FY25 | Standalone FY26 | Standalone FY25 |
|---|---|---|---|---|
| Total Income (including Other Income): | 1,58,727 | 1,24,256 | 1,51,530 | 1,26,177 |
| EBITDA (Profit before Finance Cost, Depreciation & Tax): | 10,563 | (5,483) | 9,866 | (5,698) |
| Finance Cost: | 4,649 | 6,495 | 3,725 | 4,948 |
| Depreciation and Amortization: | 3,196 | 2,905 | 2,133 | 1,930 |
| Profit/(Loss) before exceptional items and Tax: | 2,718 | (14,883) | 4,008 | (12,576) |
| Exceptional Income: | (1,745) | 2,926 | (1,028) | 2,926 |
| Profit/(Loss) for the year: | 457 | (9,213) | 2,274 | (7,308) |
| Total Comprehensive Income/(Loss): | 447 | (9,532) | 2,258 | (7,627) |
Key Corporate Developments in FY 2025-26
Several significant corporate events shaped the Company's trajectory during the year:
- Coromandel Acquisition: Coromandel International Limited (CIL) acquired 10,69,12,581 equity shares (53.08%) of NACL, making NACL a subsidiary of CIL with effect from August 8, 2025
- Rights Issue: The Company successfully mobilized approximately ₹249.29 Crores through a rights issue of 3,25,01,851 equity shares at ₹76.70 per share (face value ₹1, premium ₹75.70), allotted on December 31, 2025. Subsequent to the rights issue, CIL's stake increased to 53.73%
- Credit Rating Upgrade: Long-term bank facilities were upgraded to 'CRISIL AA/Stable' and short-term facilities to 'CRISIL A1+' as on November 07, 2025
- Share Capital: Paid-up equity share capital increased from ₹20,12,03,147 to ₹23,41,78,330 during the year
Business Segment Performance
The domestic retail business recorded 5% growth, with domestic retail sales of ₹67,742 Lakh against ₹64,266 Lakh in the previous year. Key segment highlights are as follows:
| Segment: | FY 2025-26 Revenue (₹ Lakh) | FY 2024-25 Revenue (₹ Lakh) | Growth |
|---|---|---|---|
| Insecticides: | 38,801 | 38,189 | 2% |
| Herbicides: | 12,724 | 11,890 | 7% |
| Fungicides: | 13,144 | 11,817 | 11% |
| Plant Growth Regulators / Bio-stimulants: | 3,073 | 2,370 | 30% |
| Domestic Institutional Sales: | 54,206 | 26,121 | — |
| International / Export Revenue: | 35,355 | 30,956 | 14% |
The international business expanded its footprint to 39 countries, recording export revenues of ₹35,355 Lakhs in FY 2025-26, a 14% year-on-year growth. Foreign exchange earned during the year was ₹35,355 Lakhs, while foreign exchange used was ₹31,370 Lakhs.
New Product Launches
During the year, the Company successfully commercialized manufacturing of the following new formulations:
| S. No.: | Product Name: | Composition: |
|---|---|---|
| 1 | Profex Ultra | Emamectin Benzoate 1.5% + Profenophos 35% WDG |
| 2 | Faita | Cyclaniliprole 10% DC |
| 3 | Jhalak | Spinosad 45% SC |
| 4 | Calyx | Chlorantraniliprole 9.3% + Lambda-Cyhalothrin 4.6% ZC |
| 5 | Tripleact | Dinotefuran 4.8% + Pymetrozine 14.8% + Fipronil 7.5% SC |
| 6 | Kadak | Azoxystrobin 4.8% w/w + Chlorothalonil 40.0% SC |
| 7 | Carnage | Ametryn 80% WG |
| 8 | Weed Sweep | Haloxyfop-R-Methyl Ester 10.5% EC |
| 9 | Weed Master | Glufosinate Ammonium 13.5% SL |
Sustainability and Operations
The Srikakulam Technical Plant achieved annual production of 11,611 MT and the Dahej plant achieved 3,031 MT during the year. The Ethakota Formulation Unit recorded production of 23,220 MT/KL. The Company maintained Zero Liquid Discharge (ZLD) systems across all manufacturing facilities and received the Environment Excellence Award at the 19th ICC Environment Partnership Summit & Awards 2025 and the CII Andhra Pradesh Industrial Safety Excellence Award 2025.
The Company has set sustainability targets by 2030, including a 25% reduction in specific energy consumption, a 30% reduction in specific GHG/CO₂ emissions, a 25% increase in renewable energy utilization, a 25% reduction in specific hazardous waste generation, and a 30% reduction in specific water consumption. The average net profits for the immediately preceding three financial years resulted in a negative figure of ₹15.21 Lakhs, and accordingly no amount was spent towards CSR activities for FY 2025-26.
Site-wise Sustainability Performance
The following table presents sustainability metrics for the Ethakota site:
| Parameter: | FY25 | FY26 | Improvement |
|---|---|---|---|
| Energy Consumption (toe/ton): | 0.016 | 0.01577 | 1.44% Reduction |
| Power Consumption (kWh/ton): | 54.39 | 54.79 | 0.73% Increase |
| Water Consumption (m³/ton): | 0.582 | 0.585 | 0.51% Increase |
| Hazardous Waste (kg/ton): | 0.015 | 0.0096 | 36.00% Reduction |
| Carbon Emissions (tCO₂e/ton): | 0.0566 | 0.0562 | 0.62% Reduction |
The Dahej facility demonstrated significant improvements across all major sustainability parameters:
| Parameter: | FY25 | FY26 | Improvement |
|---|---|---|---|
| Energy Consumption (toe/ton): | 0.78 | 0.71 | 8.97% Reduction |
| Power Consumption (kWh/ton): | 2206 | 1909 | 13.40% Reduction |
| Water Consumption (m³/ton): | 14.17 | 12.83 | 9.46% Reduction |
| Hazardous Waste (kg/ton): | 360 | 260 | 27.70% Reduction |
| Carbon Emissions (tCO₂e/ton): | 3.04 | 2.75 | 9.54% Reduction |
Overall sustainability progress compared to the FY 2022 baseline is summarised below:
| Parameter: | FY25 | FY26 | Improvement |
|---|---|---|---|
| Energy Consumption (toe/ton): | 1.64 | 1.53 | 6.71% Reduction |
| Power Consumption (kWh/ton): | 2814 | 2487 | 11.62% Reduction |
| Water Consumption (m³/ton): | 13.33 | 12.39 | 7.05% Reduction |
| Hazardous Waste (kg/ton): | 630 | 610 | 3.17% Reduction |
| Carbon Emissions (tCO₂e/ton): | 6.38 | 5.94 | 6.90% Reduction |
R&D Highlights
During the year, processes for four technical products were successfully developed, of which two were commercialized and two progressed to the pilot stage. The Company secured over 25 registrations across various categories in India, including three technical indigenous manufacturing registrations, and 10 registrations in international markets, taking the overall portfolio to 588 registrations domestically and 147 overseas. Three new patents were granted and approximately 21 new patent applications were filed. R&D expenditure for FY 2025-26 comprised capital expenditure of ₹134 Lakhs and revenue expenses of ₹1,761 Lakhs, representing 1.26% of total turnover.
Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE295D01020/838e3fa3-0025-40a2-a28a-e5cd03cf5aa1.pdf
Historical Stock Returns for NACL Industries
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.40% | +20.57% | +28.58% | +20.97% | +7.15% | +195.17% |
How will the integration with Coromandel International Limited influence NACL's market expansion and operational synergies in the coming fiscal year?
With the MD & CEO's remuneration now linked to performance pay up to 70% of basic salary, what specific strategic milestones has the board set for FY 2026-27?
Given the significant reduction in finance costs and credit rating upgrades, what are the company's capital allocation plans regarding debt repayment or future CAPEX?
18
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
